Logo image of PCLO.CA

PHARMACIELO LTD (PCLO.CA) Stock Fundamental Analysis

TSX-V:PCLO - TSX Venture Exchange - CA71716K1012 - Common Stock - Currency: CAD

0.085  0 (0%)

Fundamental Rating

0

PCLO gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 35 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of PCLO have multiple concerns. PCLO has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year PCLO has reported negative net income.
PCLO had a negative operating cash flow in the past year.
PCLO had negative earnings in each of the past 5 years.
PCLO had a negative operating cash flow in each of the past 5 years.
PCLO.CA Yearly Net Income VS EBIT VS OCF VS FCFPCLO.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -10M -20M -30M -40M

1.2 Ratios

PCLO has a worse Return On Assets (-71.19%) than 81.08% of its industry peers.
Industry RankSector Rank
ROA -71.19%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PCLO.CA Yearly ROA, ROE, ROICPCLO.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 -50 -100 -150 -200

1.3 Margins

PCLO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PCLO.CA Yearly Profit, Operating, Gross MarginsPCLO.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 0 -1K -2K -3K -4K

More info and screens

0

2. Health

2.1 Basic Checks

PCLO does not have a ROIC to compare to the WACC, probably because it is not profitable.
PCLO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PCLO.CA Yearly Shares OutstandingPCLO.CA Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 50M 100M 150M
PCLO.CA Yearly Total Debt VS Total AssetsPCLO.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M

2.2 Solvency

Based on the Altman-Z score of -13.88, we must say that PCLO is in the distress zone and has some risk of bankruptcy.
PCLO has a Altman-Z score of -13.88. This is amonst the worse of the industry: PCLO underperforms 81.08% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -13.88
ROIC/WACCN/A
WACC8.12%
PCLO.CA Yearly LT Debt VS Equity VS FCFPCLO.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 20M -20M 40M

2.3 Liquidity

PCLO has a Current Ratio of 0.15. This is a bad value and indicates that PCLO is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.15, PCLO is doing worse than 86.49% of the companies in the same industry.
A Quick Ratio of 0.07 indicates that PCLO may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.07, PCLO is doing worse than 89.19% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.15
Quick Ratio 0.07
PCLO.CA Yearly Current Assets VS Current LiabilitesPCLO.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 5M 10M 15M

More info and screens

0

3. Growth

3.1 Past

PCLO shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -1.95%.
The Revenue has decreased by -7.61% in the past year.
PCLO shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -16.56% yearly.
EPS 1Y (TTM)-1.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.24%
Revenue 1Y (TTM)-7.61%
Revenue growth 3Y-16.56%
Revenue growth 5YN/A
Sales Q2Q%277.85%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PCLO.CA Yearly Revenue VS EstimatesPCLO.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M
PCLO.CA Yearly EPS VS EstimatesPCLO.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 -0.1 -0.2 -0.3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PCLO. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PCLO.CA Price Earnings VS Forward Price EarningsPCLO.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PCLO.CA Per share dataPCLO.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.02 -0.04 -0.06

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

PCLO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PHARMACIELO LTD

TSX-V:PCLO (3/7/2025, 7:00:00 PM)

0.085

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-27 2024-11-27
Earnings (Next)06-30 2025-06-30
Inst Owners4.58%
Inst Owner ChangeN/A
Ins Owners8.82%
Ins Owner ChangeN/A
Market Cap14.94M
Analysts80
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.75
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.08
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0.01
BVpS-0.04
TBVpS-0.04
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -71.19%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.13
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.15
Quick Ratio 0.07
Altman-Z -13.88
F-Score3
WACC8.12%
ROIC/WACCN/A
Cap/Depr(3y)41.57%
Cap/Depr(5y)273.09%
Cap/Sales(3y)23.11%
Cap/Sales(5y)345.87%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.24%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-7.61%
Revenue growth 3Y-16.56%
Revenue growth 5YN/A
Sales Q2Q%277.85%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y34.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y76.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y75.48%
OCF growth 3YN/A
OCF growth 5YN/A